Back to News
Market Impact: 0.3
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Source: benzinga.com
Healthcare & BiotechAntitrust & Competition
Dyne Therapeutics shares traded lower Tuesday following Novartis' release of global Phase 3 HARBOR study data for del-desiran in myotonic dystrophy type 1. The reaction highlights increased competitive pressure in the DM1 treatment market, though the article provides no clinical efficacy, safety, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
DYN-0.45
NVS0.50
More News
- Cholesterol drug setback casts doubt over multibillion-dollar race
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
- Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
- Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries